Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of ASAQ and AL for Uncomplicated Malaria in Liberia
NCT06300970Phase 4Completed
- Sponsor
- Centers for Disease Control and Prevention
- Start
- Aug 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Plasmodium falciparum malaria comparing Artesunate+Amodiaquine with Artemether+Lumefantrine (2 arms). Primary endpoints: Number of Participants with Early Treatment Failure (ETF), Number of Participants with Late Treatment Failure (LTF) and 1 more. Started Aug 2022; status: completed.
02
Drugs
artesunate + amodiaquineartemether + lumefantrine
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT06300970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06300970.